Search

everythinglearnresearchcommunity

for

Search:↓

Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.

Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.

Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.

Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.

The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

Topical ruxolitinib cream may help treat frontal fibrosing alopecia.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.

Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Promising cancer treatments were found, but the manufacturer closed.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

The muscle damage was caused by T-cell large granular lymphocytic leukemia, not dermatomyositis.

Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.